This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Vivoryon Therapeutics Crescita futura
Future criteri di controllo 3/6
Vivoryon Therapeutics is forecast to grow earnings and revenue by 71.8% and 65.1% per annum respectively. EPS is expected to decline by 8.4% per annum. Return on equity is forecast to be -135.7% in 3 years.
Informazioni chiave
71.8%
Tasso di crescita degli utili
-8.4%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 35.4% |
| Tasso di crescita dei ricavi | 65.1% |
| Rendimento futuro del capitale proprio | -135.7% |
| Copertura analitica | Low |
| Ultimo aggiornamento | n/a |
Aggiornamenti recenti sulla crescita futura
Recent updates
Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2024 | 20 | 1 | N/A | 48 | 1 |
| 12/31/2023 | 6 | -10 | -16 | -10 | 2 |
| 12/31/2022 | N/A | -13 | -12 | -12 | 2 |
| 12/31/2021 | 11 | -13 | -11 | -11 | N/A |
| 9/30/2021 | 11 | -12 | -11 | -11 | N/A |
| 6/30/2021 | N/A | -21 | -14 | -14 | N/A |
| 3/31/2021 | N/A | -19 | -14 | -14 | N/A |
| 12/31/2020 | N/A | -17 | -15 | -14 | N/A |
| 9/30/2020 | N/A | -15 | -15 | -15 | N/A |
| 6/30/2020 | N/A | -12 | -15 | -15 | N/A |
| 3/31/2020 | N/A | -10 | -13 | -13 | N/A |
| 12/31/2019 | N/A | -8 | -12 | -12 | N/A |
| 9/30/2019 | N/A | -7 | -9 | -9 | N/A |
| 6/30/2019 | N/A | -7 | -6 | -6 | N/A |
| 3/31/2019 | N/A | -7 | -7 | -7 | N/A |
| 12/31/2018 | N/A | -8 | -7 | -7 | N/A |
| 9/30/2018 | N/A | -8 | -8 | -8 | N/A |
| 6/30/2018 | N/A | -8 | -9 | -9 | N/A |
| 3/31/2018 | N/A | -8 | -10 | -10 | N/A |
| 12/31/2017 | N/A | -8 | -12 | -12 | N/A |
| 9/30/2017 | N/A | -10 | -13 | -13 | N/A |
| 6/30/2017 | N/A | -12 | -14 | -14 | N/A |
| 3/31/2017 | N/A | -13 | -14 | -14 | N/A |
| 12/31/2016 | N/A | -14 | -13 | -13 | N/A |
| 9/30/2016 | N/A | -14 | -13 | -13 | N/A |
| 6/30/2016 | N/A | -13 | -13 | -13 | N/A |
| 3/31/2016 | N/A | -13 | -13 | -13 | N/A |
| 12/31/2015 | N/A | -14 | -12 | -12 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: 05Y is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.01%).
Guadagni vs Mercato: 05Y is forecast to become profitable over the next 3 years, which is considered above average market growth.
Guadagni ad alta crescita: 05Y is expected to become profitable in the next 3 years.
Ricavi vs Mercato: 05Y is forecast to have no revenue next year.
Ricavi ad alta crescita: 05Y is forecast to have no revenue next year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: 05Y is forecast to be unprofitable in 3 years.